15.57
0.03 (0.16%)
| Penutupan Terdahulu | 15.54 |
| Buka | 15.54 |
| Jumlah Dagangan | 898,447 |
| Purata Dagangan (3B) | 5,561,026 |
| Modal Pasaran | 4,818,718,720 |
| Harga / Buku (P/B) | 1.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Mar 2026 |
| EPS Cair (TTM) | -0.570 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.72% |
| Nisbah Semasa (MRQ) | 12.35 |
| Aliran Tunai Operasi (OCF TTM) | -107.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -91.89 M |
| Pulangan Atas Aset (ROA TTM) | -22.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Erasca, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.38 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.69% |
| % Dimiliki oleh Institusi | 84.38% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (Clear Street, 28.49%) | Beli |
| Median | 15.00 (-3.63%) | |
| Rendah | 11.00 (Piper Sandler, -29.33%) | Beli |
| Purata | 15.33 (-1.51%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 11.60 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Clear Street | 06 Mar 2026 | 20.00 (28.49%) | Beli | 15.57 |
| HC Wainwright & Co. | 26 Jan 2026 | 15.00 (-3.63%) | Beli | 9.61 |
| 13 Jan 2026 | 11.00 (-29.33%) | Beli | 7.51 | |
| Piper Sandler | 16 Jan 2026 | 11.00 (-29.33%) | Beli | 9.62 |
| 07 Jan 2026 | 5.00 (-67.88%) | Beli | 5.17 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Erasca to Present at Upcoming Conferences in February |
| 23 Jan 2026 | Pengumuman | Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 21 Jan 2026 | Pengumuman | Erasca Announces Pricing of Upsized Public Offering of Common Stock |
| 20 Jan 2026 | Pengumuman | Erasca Announces Proposed Public Offering of $150 Million of Common Stock |
| 14 Jan 2026 | Pengumuman | Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff |
| 12 Jan 2026 | Pengumuman | Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones |
| 06 Jan 2026 | Pengumuman | Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |